{"id":"anti-tumour-necrosis-factor-antibodies","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased infection risk (including tuberculosis and opportunistic infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Demyelinating disease (rare)"}]},"_chembl":{"chemblId":"CHEMBL2074849","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF-α is a central mediator of inflammation and plays a critical role in various autoimmune and inflammatory diseases. By blocking TNF-α signaling through direct antibody binding, these agents suppress the inflammatory cascade and reduce pathological immune activation. This mechanism has proven effective in conditions driven by excessive TNF-α production, including rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders.","oneSentence":"Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:51.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Ankylosing spondylitis"},{"name":"Psoriasis and psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT05960578","phase":"PHASE2","title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-05-23","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":8},{"nctId":"NCT02508012","phase":"NA","title":"Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-09-24","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":260},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT06441526","phase":"PHASE3","title":"Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-09-14","conditions":"Perianal Fistula, Crohn Disease","enrollment":94},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT02492217","phase":"PHASE4","title":"Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients","status":"COMPLETED","sponsor":"Universidade Nova de Lisboa","startDate":"2015-05","conditions":"Ankylosing Spondylitis","enrollment":69},{"nctId":"NCT01590966","phase":"PHASE3","title":"Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-10-18","conditions":"Axial and Peripheral Spondyloarthritis, Rheumatoid Arthritis","enrollment":41},{"nctId":"NCT00356408","phase":"PHASE3","title":"Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-01","conditions":"Crohn's Disease","enrollment":106},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01350804","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":551},{"nctId":"NCT01237262","phase":"PHASE4","title":"Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2010-11","conditions":"Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"anti-tumour necrosis factor α antibodies","genericName":"anti-tumour necrosis factor α antibodies","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}